FDMT P/E Ratio
P/E Ratio as of Jun 13, 2025: -1.30
Average-1.16
Median-1.13
Minimum-1.42
Maximum-1.02
-1.30
Past Month-0.35 (36.84%)
The P/E ratio for FDMT is -1.30 as of Jun 13, 2025. This represents a decrease of -58.73% compared to its 12-month average P/E ratio of -3.15. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
4D Molecular Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
4D Molecular Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing 4D Molecular Therapeutics to industry peers.
4D Molecular Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
4D Molecular Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing 4D Molecular Therapeutics to industry peers.
FDMT P/E Ratio Insights
See 4D Molecular Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in FDMT
Order type
Buy in
Order amount
Est. shares
0 shares
FDMT P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Jun 2, 2025 | $3.75 | -1.11 |
| May 1, 2025 | $3.44 | -1.09 |
| Apr 1, 2025 | $2.99 | -0.95 |
| Mar 3, 2025 | $4.14 | -1.31 |
| Feb 3, 2025 | $5.93 | -2.17 |
| Jan 2, 2025 | $5.83 | -2.13 |
FDMT End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -1.30 | -36.27% |
| 2024 | -2.04 | -72.47% |
| 2023 | -7.41 | +10.93% |
| 2022 | -6.68 | -21.78% |
| 2021 | -8.54 | -59.41% |
| 2020 | -21.04 | — |
FAQs About 4D Molecular Therapeutics (FDMT) P/E ratio
The latest P/E ratio of FDMT is -1.30, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
4D Molecular Therapeutics’s last 12-month average P/E ratio is -3.15, compared to its current P/E ratio of -1.30. This reflects a decrease of -58.73%.
4D Molecular Therapeutics’s current P/E ratio of -1.30 is lower than its last 12-month average P/E of -3.15. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
4D Molecular Therapeutics’s average P/E ratio over the last 3 years is -4.86. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
4D Molecular Therapeutics’s average P/E ratio over the last 5 years is -6.91. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.